CN Patent

CN115569113B — 一种盐酸缬更昔洛韦口服溶液

Assigned to Jiangsu Hanchen Pharmaceutical Co ltd · Expires 2023-11-10 · 3y expired

What this patent protects

本发明涉及一种盐酸缬更昔洛韦口服溶液。具体地，本发明提供一种盐酸缬更昔洛韦口服溶液，所述的盐酸缬更昔洛韦口服溶液包括盐酸缬更昔洛韦、乙醇、甘油、聚乙二醇400、三氯蔗糖、山梨醇、甘露醇、卵磷脂、聚乙烯醇、酒石酸、亚硫酸氢钠、氯化钠和水。本发明所述的盐酸缬更昔洛韦口服溶液具有优异的稳定性，从而具有优异的存储和运输稳定性，保证药物质量，进而有效保证盐酸缬更昔洛韦口服溶液的用药安全性。

USPTO Abstract

本发明涉及一种盐酸缬更昔洛韦口服溶液。具体地，本发明提供一种盐酸缬更昔洛韦口服溶液，所述的盐酸缬更昔洛韦口服溶液包括盐酸缬更昔洛韦、乙醇、甘油、聚乙二醇400、三氯蔗糖、山梨醇、甘露醇、卵磷脂、聚乙烯醇、酒石酸、亚硫酸氢钠、氯化钠和水。本发明所述的盐酸缬更昔洛韦口服溶液具有优异的稳定性，从而具有优异的存储和运输稳定性，保证药物质量，进而有效保证盐酸缬更昔洛韦口服溶液的用药安全性。

Drugs covered by this patent

Patent Metadata

Patent number
CN115569113B
Jurisdiction
CN
Classification
—
Expires
2023-11-10
Drug substance claim
No
Drug product claim
No
Assignee
Jiangsu Hanchen Pharmaceutical Co ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.